MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.repc.2026.04.007

Медицинская библиотека · Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology · 2026

Impact of sodium-glucose cotransporter 2 inhibitors on blood glucose levels in patients with heart failure with reduced ejection fraction without diabetes.

Abd El Hady Yasser Ahmed, Abd Elaziz Abd Allah Shahat Ali, Adly Mahmoud Abeer

СтатьяРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

INTRODUCTION AND

OBJECTIVES

Sodium-glucose cotransporter 2 inhibitors (SGLT2) were initially developed as antihyperglycemic agents for the management of type 2 diabetes mellitus (T2DM). This study sought to evaluate the impact of sodium-glucose cotransporter 2 inhibitors on blood glucose levels in patients with HFrEF without diabetes.

METHODS

This randomized controlled trial included 130 patients with HF classified as NYHA class II to IV and without diabetes, with an ejection fraction (EF) below 40% as determined by echocardiography within the preceding three months. Baseline assessments included serum creatinine, random and fasting blood glucose, 2-hour postprandial glucose, HbA1c, urine acetone, BMI, blood pressure, and serum electrolytes (sodium, potassium, magnesium, ionized calcium, and phosphorus). After three months of treatment, all these clinical and laboratory parameters were reassessed in both groups.

RESULTS

Treatment led to significant improvements in cardiac function, including reductions in left ventricular diameters and volumes, and increases in ejection fraction, tricuspid annular plane systolic excursion, and right ventricular fractional area change (p<0.05). Glycemic control also improved, with significant decreases in fasting, postprandial, HbA1c, and random blood glucose (p<0.001). Serum creatinine, magnesium, and phosphorus levels increased significantly (p<0.001). Adverse events were minimal, with only one patient showing urine acetone positivity (1.5%, p=0.99), and no symptomatic hypoglycemia, ketoacidosis, or significant hypotension occurred.

CONCLUSIONS

SGLT2 inhibitors safely reduce blood glucose in patients with HFrEF without diabetes without causing hypoglycemia, highlighting their potential cardiovascular and metabolic benefits and supporting their use in this population.

Для цитирования: Abd El Hady Yasser Ahmed, Abd Elaziz Abd Allah Shahat Ali, Adly Mahmoud Abeer. Impact of sodium-glucose cotransporter 2 inhibitors on blood glucose levels in patients with heart failure with reduced ejection fraction without diabetes.. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology. 2026. DOI: 10.1016/j.repc.2026.04.007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.